#### DIPHENHYDRAMINE HYDROCHLORIDE - diphenhydramine hydrochloride injection Gland Pharma Limited


-----

Diphenhydramine Hydrochloride Injection, USP Rx only

### DESCRIPTION

Diphenhydramine Hydrochloride Injection is a sterile, nonpyrogenic solution for intravenous or deep intramuscular use as an antihistaminic agent. Each mL contains diphenhydramine hydrochloride USP 50 mg in Water for Injection. pH 4.0 to 6.5; sodium hydroxide and/or hydrochloric acid added, if needed, for pH adjustment.

The chemical name of diphenhydramine hydrochloride is 2-(Diphenylmethoxy)-N, Ndimethylethylamine hydrochloride. The structural formula is as follows:



C<sub>17</sub>H<sub>21</sub>NO • HCl MW 291.82 Diphenhydramine hydrochloride occurs as a white crystalline powder and is freely soluble in water and alcohol.

# **CLINICAL PHARMACOLOGY**

Diphenhydramine hydrochloride is an antihistamine with anticholinergic (drying) and sedative side effects. Antihistamines appear to compete with histamine for cell receptor sites on effector cells.

Diphenhydramine hydrochloride in the injectable form has a rapid onset of action. Diphenhydramine is widely distributed throughout the body, including the CNS. A portion of the drug is excreted unchanged in the urine, while the rest is metabolized via the liver. Detailed information on the pharmacokinetics of Diphenhydramine Hydrochloride Injection is not available.

# INDICATIONS AND USAGE

Diphenhydramine Hydrochloride Injection is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when the oral form is impractical:

### Antihistaminic

For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated.

### **Motion Sickness**

For active treatment of motion sickness.

### Antiparkinsonism

For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents, mild cases of parkinsonism in other age groups and in other cases of parkinsonism in combination with centrally acting anticholinergic agents.

# CONTRAINDICATIONS

### **Use in Neonates or Premature Infants**

This drug should not be used in neonates or premature infants.

### **Use in Nursing Mothers**

Because of the higher risk of antihistamines for infants generally, and for neonates and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.

### Use as a Local Anesthetic

Because of the risk of local necrosis, this drug should not be used as a local anesthetic.

# Antihistamines are also Contraindicated in the Following Conditions

Hypersensitivity to diphenhydramine hydrochloride and other antihistamines of similar chemical structure.

### WARNINGS

Antihistamines should be used with considerable caution in patients with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic

hypertrophy or bladder-neck obstruction.

Local necrosis has been associated with the use of subcutaneous or intradermal use of intravenous diphenhydramine.

# Use in Pediatric Patients

In pediatric patients, especially, antihistamines in overdosage may cause hallucinations, convulsions or death.

As in adults, antihistamines may diminish mental alertness in pediatric patients. In the young pediatric patient, particularly, they may produce excitation.

# Use in the Elderly (approximately 60 years or older)

Antihistamines are more likely to cause dizziness, sedation and hypotension in elderly patients.

# PRECAUTIONS

# General

Diphenhydramine hydrochloride has an atropine-like action and, therefore, should be used with caution in patients with a history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease or hypertension. Use with caution in patients with lower respiratory disease, including asthma.

# Information for Patients

Patients taking diphenhydramine hydrochloride should be advised that this drug may cause drowsiness and has an additive effect with alcohol.

Patients should be warned about engaging in activities requiring mental alertness, such as driving a car or operating appliances, machinery, etc.

# **Drug Interactions**

Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.)

MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.

# Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals to determine mutagenic and carcinogenic potential have not been performed.

### Pregnancy

**Teratogenic Effects** 

Reproduction studies have been performed in rats and rabbits at doses up to 5 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to diphenhydramine hydrochloride. There are, however, no adequate and wellcontrolled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

### **Pediatric Use**

Diphenhydramine should not be used in neonates and premature infants (see **CONTRAINDICATIONS**).

Diphenhydramine may diminish mental alertness, or in the young pediatric patient, cause excitation. Overdosage may cause hallucinations, convulsions or death (see **WARNINGS** and **OVERDOSAGE**).

See also **DOSAGE AND ADMINISTRATION** section.

# ADVERSE REACTIONS

The most frequent adverse reactions are italicized.

### General

Urticaria; drug rash; anaphylactic shock; photosensitivity; excessive perspiration; chills; dryness of mouth, nose and throat.

### Cardiovascular System

Hypotension, headache, palpitations, tachycardia, extrasystoles.

### Hematologic System

Hemolytic anemia, thrombocytopenia, agranulocytosis.

# **Nervous System**

*Sedation, sleepiness, dizziness, disturbed coordination,* fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, neuritis, convulsions.

# **Gastrointestinal System**

*Epigastric distress*, anorexia, nausea, vomiting, diarrhea, constipation.

### **Genitourinary System**

Urinary frequency, difficult urination, urinary retention, early menses.

### **Respiratory System**

*Thickening of bronchial secretions*, tightness of chest and wheezing, nasal stuffiness.

# OVERDOSAGE

Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. Stimulation is particularly likely in pediatric patients. Atropine-like signs and symptoms, dry mouth; fixed, dilated pupils; flushing, and gastrointestinal symptoms may also occur.

*Stimulants* should **not** be used.

Vasopressors may be used to treat hypotension.

# DOSAGE AND ADMINISTRATION

THIS PRODUCT IS FOR INTRAVENOUS OR INTRAMUSCULAR ADMINISTRATION ONLY.

Diphenhydramine Hydrochloride Injection is indicated when the oral form is impractical.

DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.

### Pediatric Patients, Other Than Premature Infants and Neonates

5 mg/kg/24 hours or 150 mg/m<sup>2</sup>/24 hours. Maximum daily dosage is 300 mg. Divide into four doses, administered intravenously at a rate generally not exceeding 25 mg/min, or deep intramuscularly.

# Adults

10 to 50 mg intravenously at a rate generally not exceeding 25 mg/min, or deep intramuscularly; 100 mg if required; maximum daily dosage is 400 mg.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

### HOW SUPPLIED

Diphenhydramine Hydrochloride Injection, USP 50 mg/mL

1 mL fill in 2 mL single-dose vial packaged in 25s (NDC 68083-611-25)

### Storage

Protect from light. Keep covered in carton until time of use. Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

### **Discard Unused Portion.**


To report SUSPECTED ADVERSE REACTIONS, contact Gland Pharma Limited at 609-250-7990, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For Product Inquiry call 609-250-7990.

### Manufactured by:

Gland Pharma Limited Pashamylaram, Patancheru, Hyderabad – 502307, India Issued: 03/2023


### PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Container Label NDC 68083-611-01 Rx only diphenhydrAMINE Hydrochloride Injection, USP 50 mg/mL HIGH POTENCY For Intramuscular or Intravenous Use Protect From Light 1 mL Single- Dose Vial



Carton Label

NDC 68083-611-25 Rx only diphenhydrAMINE Hydrochloride Injection, USP 50 mg/mL HIGH POTENCY For Deep Intramuscular or Slow Intravenous Use Discard Unused Portion 25 x 1 mL Single-Dose Vials



# DIPHENHYDRAMINE HYDROCHLORIDE

HybrochLoric Acid (UNII: QTT17582CB)     Warketing Start     Warketing Start     Marketing Start     Marketing Start     25 in 1 CARTON   03/20/2024     1   NDC:68083-611-   25 in 1 CARTON     25 in 1 CARTON   03/20/2024     ImmL in 1 VIAL; Type 0: Not a Combination Product									
Product Type   HUMAN PRESCRIPTION DRUG   Item Code (Source)   NDC:68083-611     Route of Administration   INTRAMUSCULAR, INTRAVENOUS   NDC:68083-611   Strength     Active Ingredient/Active Moiety     Ingredient Name   Basis of Strength   Strength     DIPHENHYDRAMINE HYDROCHLORIDE (UMII: TC2D6JAD40)   DIPHENHYDRAMINE - UNII:8GTS82583M)   DIPHENHYDRAMINE   50 mg   in 1 mL     Ingredient Name   Strength     Strength     Ingredient Name   Strength     Strength   Strength <	diphenhydramine	e hydrochlorio	de injection						
Product Type   HUMAN PRESCRIPTION DRUG   Item Code (Source)   NDC:68083-611     Route of Administration   INTRAMUSCULAR, INTRAVENOUS   NDC:68083-611   Strength     Active Ingredient/Active Moiety     Ingredient Name   Basis of Strength   Strength     DIPHENHYDRAMINE HYDROCHLORIDE (UMII: TC2D6JAD40)   DIPHENHYDRAMINE - UNII:8GTS82583M)   DIPHENHYDRAMINE   50 mg   in 1 mL     Ingredient Name   Strength     Strength     Ingredient Name   Strength     Strength   Strength <									
NTRAMUSCULAR, INTRAVENOUS     Active Ingredient/Active Moiety     Ingredient Name   Basis of Strength   Strength     DIPHENHYDRAMINE + HYDROCHLORIDE (UNII: TC2D6)AD40)   DIPHENHYDRAMINE + S0 mg     Ingredient Name   So mg     Ingredient Name   Strength     So mg     Ingredient Name   Strength     So mg     Ingredient Name   Strength     So Migredient Name   So Migredient Name     Strength   Marketing End<	Product Infor	mation							
Active Ingredient/Active Moiety     Ingredient Name   Basis of Strength   Strength     DIPHENHYDRAMINE HYDROCHLORIDE (UNII: TC2D6JAD40)   DIPHENHYDRAMINE   50 mg   in 1 mL     Ingredient Name   S00000000000000000000000000000000000	Product Type		HUMAN PRESCRIPTION DRUG Item Code (Sour			:e) NDC:68083-611			
Ingredient Name   Basis of Strength   Strength     DIPHENHYDRAMINE HYDROCHLORIDE (UNII: TC2D6JAD40)   DIPHENHYDRAMINE HYDROCHLORIDE   So mg in 1 mL     Ingredient Name   So mg in 1 mL     Ingredient Name   Strength     Solum HyDROXIDE (UNII: S5X04QC32I)   Strength     HyDROCHLORIC ACID (UNII: QTT17582CB)   Solum HyDROXIDE (UNII: S5X04QC32I)     HyDROCHLORIC ACID (UNII: QTT17582CB)   Strength     Varter (UNII: 059QF0KOOR)   Strength     Distent Colspan="2">Marketing Start Date   Marketing End Date     NDC:68083-611- 25 in 1 CARTON   03/20/2024     Imarketing Liformation     Marketing Information     Marketing Liformation     Marketing Category   Application Number or Monograph Citation   Marketing Start Date   Marketing End Date	Route of Admini	istration	INTRAMUSCULAR, INTRAVENOUS						
Ingredient Name   Basis of Strength   Strength     DIPHENHYDRAMINE HYDROCHLORIDE (UNII: TC2D6JAD40)   DIPHENHYDRAMINE HYDROCHLORIDE   So mg in 1 mL     Ingredient Name   So mg in 1 mL     Ingredient Name   Strength     Solum HyDROXIDE (UNII: S5X04QC32I)   Strength     HyDROCHLORIC ACID (UNII: QTT17582CB)   Solum HyDROXIDE (UNII: S5X04QC32I)     HyDROCHLORIC ACID (UNII: QTT17582CB)   Strength     Varter (UNII: 059QF0KOOR)   Strength     Distent Colspan="2">Marketing Start Date   Marketing End Date     NDC:68083-611- 25 in 1 CARTON   03/20/2024     Imarketing Liformation     Marketing Information     Marketing Liformation     Marketing Category   Application Number or Monograph Citation   Marketing Start Date   Marketing End Date									
Ingredient Name   Basis of Strength   Strength     DIPHENHYDRAMINE HYDROCHLORIDE (UNII: TC2D6JAD40)   DIPHENHYDRAMINE   50 mg   in 1 mL     INJERCENTS     Ingredient Name   Strength     Solum HydroCHLORIDE (UNII: S5X04QC32I)     HydroCHLORIC ACID (UNII: S5X04QC32I)     HydroCHLORIC ACID (UNII: OTT17582CB)     WATER (UNII: 0590F0K00R)     Fackaging     Marketing Start     Marketing LI CARTON     NDC:68083-611-     25 in 1 CARTON     NDC:68083-611-     25 in 1 CARTON     Nation     Marketing Information	Active Ingredi	ent/Active	Moietv						
DIPHENHYDRAMINE HYDROCHLORIDE (UNII: TC2D6JAD40)   DIPHENHYDRAMINE hydrochloride   50 mg in 1 mL     In active Ingredient Name   Strength     SODIUM HYDROXIDE (UNII: 55X04QC32))   Strength     HYDROCHLORIC ACID (UNII: 55X04QC32))   Strength     WATER (UNII: 0590F0K00R)   Strength     Variable (UNII: 0500F0K00R)   Strength     Bigging   Marketing Start     Marketing In 1 VIAL; Type 0: Not a Combination   Sol/20/2024     In Lin 1 VIAL; Type 0: Not a Combination   Improduct     Product   Packaige Description   Marketing Start     Marketing Improduct   Application Number or Monograph   Marketing Start   Marketing End Date	jj-	Basis of S	trength	Strength					
Ingredient Name   Strength     Marketing Start			DRIDE (UNII: TC2D6JAD40)		DIPHENHYDRAMINE 50 mg		50 mg		
Ingredient Name   Strength     Marketing Start									
SOIUM HYDROXIDE (UNII: 55X04QC32I)   Image: Constant of the second sec	Inactive Ingre	dients							
HybrochLoric Acid (UNII: QTT17582CB)     Warketing Start     Warketing Start     Marketing Start     Marketing Start     25 in 1 CARTON   03/20/2024     1   NDC:68083-611-   25 in 1 CARTON     25 in 1 CARTON   03/20/2024     ImmL in 1 VIAL; Type 0: Not a Combination Product	Ingredient Name						Strength		
WATER (UNII: 059QF0K00R)     Marketing Start     Warketing Start     #   Item Code   Package Description   Marketing Start   Marketing End Date     1   NDC: 68083-611- 25   25 in 1 CARTON   03/20/2024   03/20/2024     1   1 mL in 1 VIAL; Type 0: Not a Combination Product   1   1   1     Marketing End Date     Marketing Start Marketing End Date	SODIUM HYDROXIDE (UNII: 55X04QC32I)								
Marketing Start Date     #   Item Code   Package Description   Marketing Start Date   Marketing End Date     1   NDC:68083-611- 25 in 1 CARTON   03/20/2024   03/20/2024     1   ImL in 1 VIAL; Type 0: Not a Combination Product   ImL in 1 VIAL; Type 0: Not a Combination Product   ImL in 1 VIAL; Type 0: Not a Combination Product     Marketing Category     Marketing Citation Number or Monograph Date   Marketing Start Date   Marketing End Date			L7582CB)						
Item Code   Package Description   Marketing Start Date   Marketing End Date     1   NDC:68083-611- 25 in 1 CARTON   03/20/2024   Imbound   Imbound     1   Imbound   Imbound   Imbound   Imbound   Imbound     1   Imbound   Imbound   Imbound   Imbound   Imbound   Imbound     1   Imbound	WATER (UNII: 059Q	F0KO0R)							
Item Code   Package Description   Marketing Start Date   Marketing End Date     1   NDC:68083-611- 25 in 1 CARTON   03/20/2024   Imbound     1   Imbound   Imbound   Imbound   Imbound     1   Imbound   Imbound   Imbound   Imbound   Imbound     1   Imbound   Imbound   Imbound   Imbound   Imbound   Imbound     1   Imbound   Imbound   Imbound   Imbound   Imbound   Imbound   Imbound   Imbound     1   Imbound   Imbound <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>									
Item Code   Package Description   Marketing Start Date   Marketing End Date     1   NDC:68083-611- 25 in 1 CARTON   03/20/2024   Imbound   Imbound     1   Imbound   Imbound   Imbound   Imbound   Imbound     1   Imbound   Imbound   Imbound   Imbound   Imbound   Imbound     1   Imbound	Packaging								
1   25   1 mL in 1 VIAL; Type 0: Not a Combination     Product   9     Marketing Information     Marketing Category   Application Number or Monograph Citation     Marketing Start Date   Marketing End Date	# Item Code	Pac	Package Description						
Product     Marketing Information     Marketing Category   Application Number or Monograph Citation		25 in 1 CARTO	N	03/20/20	24				
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date	1		; Type 0: Not a Combination						
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date									
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date	Marketing Information								
	Marketing		tion Number or Monograph	n Ma					
	ANDA	ANDA218448		03/20	)/2024				

# Labeler - Gland Pharma Limited (918601238)

Establishment							
Name	Address	ID/FEI	Business Operations				
Gland Pharma Limited		858971074	ANALYSIS(68083-611), MANUFACTURE(68083-611), PACK(68083-611)				

Revised: 3/2024

Gland Pharma Limited